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Parkinson's disease (PD) has many possible treatment options. The main therapy 
uses a drug called levodopa. However after prolonged use, this drug begins to wear 
off and becomes less effective. Therefore additional drugs are needed to help 
ensure the patient is comfortable and to aid the relief of symptoms that can often 
occur. The addition of the COMT inhibitor, entacapone, aims to reduce motor 
symptoms and smooth out fluctuations that can sometimes be experienced with 
levodopa therapy. These can include bradykinesia, which is slowness of movement 
and help to control the resting tremor that is often associated with PD. The aim of 
this review is to determine if adding entacapone to existing levodopa therapy helps 
to improve patients motor symptoms and improve their ability to carry out every day 
activities; these outcomes will be measured using the unified Parkinson's disease 















Levodopa is known as the 'gold standard' in the treatment of Parkinson’s Disease 
(PD). Levodopa is a precursor molecule of dopamine. It crosses the blood brain 
barrier (BBB) and is taken up by substantia nigra neurons and converted into 
dopamine through the dopa decarboxylase and catechol-O-methyltransferase 
pathway. Levodopa is practically always administered with a dopa-decarboxylase 
inhibitor (DDCI), usually carbidopa and sometimes benserazide. The addition of the 
DDCI prevents conversion of levodopa to dopamine in the periphery by blocking the 
enzymatic pathway (Chen 2007). 
Levodopa/carbidopa is the most prescribed Parkinson's Disease (PD) medication, 
(Hauser 2009). A fundamental limitation of this treatment is the development of 
motor fluctuations and dyskinesias. This is thought to be due to the short half-life of 
levodopa which leads to pulsatile simulation of postsynaptic dopamine receptors. 
After prolonged used of Levodopa the efficacy of the drug is reduced, hence the 
need for additional drugs. A number of available drugs can be added to levodopa but 
one of the most effective is the addition of a catechol-O-methyltransferase inhibitor 
(COMT inhibitor). COMT inhibitors can smooth out fluctuations in plasma 
concentrations of levodopa after oral administration. Although there is a selection 
available, entacapone is thought to be tolerated the best. It is used as an adjunct to 
each daily levodopa/DDCI dose, it extends the half-life of levodopa and this 
increases the bioavailability of the drug; consequently prolonging each dose of 
levodopa (Maranis 2011). 
By combining Levodopa/DDCI/Entacapone it prevents degradation of the agents in 
the plasma and therefore allowing prolonged therapeutic levels of the drugs in the 
brain. 
Description of the condition  
Parkinson's Disease (PD) is a chronic progressive neurodegenerative disease that 
affects the central nervous system (CNS). It was first identified by Dr James 
Parkinson in 1817 and was described as 'shakey palsy' due to the nature and 
symptoms that can be displayed during the disease (Lo 2007). Symptoms that can 
occur can be divided into 2 categories: motor and non-motor symptoms. Typical 
motor symptoms that can be experienced include: bradykinesia, rigidity, tremor, and 
postural instability with an asymmetric onset spreading to become bilateral with time. 
Other motor features include: gait and posture changes that can be seen as rapid 
shuffling steps with a forward-flexed posture when walking, speech and swallowing 
difficulties, masklike facial expression and micrographia (Korczyn 2010). Non-motor 
symptoms that can be observed can include: depression, sleep disturbance, sensory 
abnormalities, autonomic dysfunction, and cognitive decline. 
PD affects over 6 million people worldwide making it the second most common 
neurodegenerative disease after Alzheimers (Ford 2010). PD has a significant 
impact on disability and quality of life, and its prevalence is thought to increase along 
with life expectancy (Braga 2014). Risk factors such as aging, genetic susceptibility, 
and environmental factors all play a role in the onset of the pathogenic process but 
how these interlink to cause neuronal loss is unknown (Dexter 2013) . Currently, 
there is no known cure for PD, consequently, treatments available aim to reduce the 
symptoms and help patients to deal with their disease. PD is characterized by the 
presence of intracytoplasmic inclusions from Lewy bodies and the depletion of 
midbrain pigmented dopamine containing neurons in the region of the substantia 




nigra. It is thought that 80% of dopaminergic neurons are already irreversibly 
destroyed when the first symptoms of PD become significantly visible (Singh 2007). 
PD cannot currently be diagnosed until there is extensive loss of the dopaminergic 
neurons from the substantia nigra pars compacta (snpc), however in recent years of 
research it has become apparent that pathology of PD doesn't actually begin in the 
snpc. It is thought that Lewy body pathology and the decomposition of a-synuclein 
originate in the olfactory bulb and lower brain stem and from there they spread to the 
mid brain and cortical regions, eventually reaching the snpc (Korczyn 2010). 
As with many drugs there are often side effects produced. Many patients that are 
treated with levodopa often experience motor complications and fluctuations, as well 
as dyskinesias. If these symptoms arise clinicians may choose to add additional 
drugs to the patients existing therapy. With such a competitive market it can be 
difficult to conclude which drug is best from the vast variety available. This choice 
can often be dependent on each patient’s individual circumstances as well as other 
factors. A selection of the drugs available are: Monoamine oxidase (MAO) inhibitors, 
dopamine agonists, catechol-O-methyltransferase inhibitor (COMT inhibitor). MAO 
inhibitors are thought to slow down the deterioration of dopamine and reduce 
oxidative stress in neurons, the most commonly used are selegiline and rasagiline. 
However in drug trials they have often produced contradictory findings that lack 
reproducible results (Williams 2010). Dopamine agonists are an option for the 
treatment of PD as an alternative to levodopa. Even though they do provide 
symptomatic benefit, they are associated with more side effects than standard 
levodopa therapy and can include: hallucinations, edema, impulse and control 
disorders and sudden sleep attacks. On the other hand, motor fluctuations and 
dyskinesias are less common from dopamine agonists compared to levodopa 
(Hickey 2011). 
There are also non-pharmacological treatments available such as cognitive 
behavioural therapy, and deep brain stimulation. These two different approaches 
have been available for a while but recent advances and technologies are always 
being created. 
Description of the intervention  
It was in the 1990's that the structures of the 2 isoforms of the COMT enzyme and 
COMT gene were identified. The COMT gene is located on chromosome 22, band 
q11.2 and consists of 6 exons (Lee 2002). COMT enzyme is located throughout the 
body and can be found in high concentrations in peripheral organs such as the liver, 
kidney and intestines. The main function of COMT is to inactivate biologically active 
or toxic catechols. In the presence of Mg2+ it catalyses the transfer of the methyl 
group of S-adenosyl-Z-methionine to one of the hydroxyl groups of the catechol 
substrate; levodopa and dopamine are substrates of COMT. 
COMT enzyme can catalyse the metabolism of levodopa to 3-O-methyldopa, 
therefore COMT inhibitor drugs prolong the maintenance of serum levodopa levels to 
produce a longer and more stable clinical levodopa response therefore leading to 
less frequent fluctuations in the patients’ clinical condition. The 2 main COMT 
inhibitors that are used in practise are entacapone and tolcapone. Entacapone is 
thought to be best tolerated as tolcapone has been associated with liver toxicity and 
is currently only available in the USA (Maranis 2011). 
Entacapone is a specific, potent and reversible COMT inhibitor with a half-life 
elimination of 1.5-3.5 hours after oral administration. The short half-life and 




elimination combined with the reversible nature of this COMT inhibitor allows safe 
co-administration of entacapone with every levodopa/DDCI dose. It has been 
demonstrated in previous studies that entacapone significantly increases the 
average area under curve (AUC) of levodopa ( Heikkinen 2002) . 
One of the main side effects of levodopa treatment is the development of motor 
complications; they develop from the progressive loss of dopaminergic nerve 
terminals on the striatum which leads to reduced dopamine storage capacity. 
How the intervention might work  
Inhibition of COMT by entacapone prolongs the half-life of levodopa, which is 
associated with improved clinical efficacy in PD patients. Extending the half-life of 
levodopa using entacapone allows delivery of the drug in a less pulsatile way, 
consequently allowing the benefit of levodopa with a decreased risk of motor 
complications compared to levodopa alone (Marin et al 2008). Although levodopa 
can cross the blood brain barrier when administered on its own, only 1% reaches the 
central nervous system; this is due to rapid metabolism by the enzymatic pathways 
dopa-decarboxylase and catechol-O-methyltransferase. Therefore, levodopa is 
almost always administered with a DDC inhibitor which increases the amount of 
levodopa that reaches the brain. The addition of the COMT inhibitor entacapone is 
used to prevent the levodopa metabolism to 3-O-methyldopa as this is a harmful 
metabolite of levodopa (Bugamelli 2011). Consequently it is thought that when the 
combination of the 3 drugs: Levodopa+DDCI+entacapone is administered there will 
be sustained plasma levels of levodopa result in more constant dopaminergic 
stimulation in the brain, leading to a greater reduction in the manifestations of 
parkinsonian syndrome. This intervention will analyse the efficacy of entacapone as 
an adjunct to levodopa+DDCI therapy through the primary outcome measuring 
UPDRS II+III.  
Why it is important to do this review  
It is important to do this review as the last meta-analysis in this area was by Stoewe 
2010, therefore making it 4 years out of date. It was important to update this with 
more recent studies to see if the same results are still found. This review includes 
extremely recent data (Tolosa 2013); this paper has only been published online to 
date, and by including this article along with others that have not been included in 
previous meta-analyses it gives a new perspective. By combining UPDRS scores II 
and III it gives a collaboration of the patient and clinician viewpoints therefore 
producing a well-rounded overall score for improvement/effectiveness of the drug 
being tested. 
Objectives  
The objective of this meta-analysis is to determine if the COMT inhibitor, 
Entacapone, is a beneficial adjunct to Levodopa in the treatment of PD with regard to 
the UPDRS looking at combined scores II and III. Part II of the UPDRS is a self-












Criteria for considering studies for this review  
Types of studies  
All randomised, double-blind trials comparing standard levodopa treatment 
(levodopa+DDCI) against levodopa with the addition of the adjunct entacapone 
(levodopa+DDCI+entacapone), a COMT inhibitor were considered for this study. 
Types of participants  
Patients with a clinical diagnosis of Idiopathic Parkinson's Disease were included in 
the study. All patients had been using levodopa treatments previously and needed 
smoothing out of the treatment as they were experiencing 'wearing off' and 
fluctuations. Their existing PD medications had to be stable for at least 4 weeks prior 
to randomisation of the experiment. Ages of the participants ranged from 30-80.  
Types of interventions  
Levodopa+DDCI+entacapone was compared to levodopa+DDCI+(placebo). 
Entacapone was administered with levodopa plus the DDCI. The DDCI was usually 
carbidopa, in some studies benserazide was used instead. Many of the studies used 
placebo in the control group; however, as all the studies were double blind and in 
both treatment groups the medication was administered in one pill the identity of the 
treatment group was concealed in all cases. 
Types of outcome measures  
The outcome measures were the UPDRS II+III scores combines. The adverse effect, 
dyskinesia, was also measured.  
Primary outcomes  
The primary outcome of this meta-analysis is the combined UPDRS II+III scores. 
The UPDRS was originally developed in the 1980s and is now the most widely used 
rating scale of PD (Gotez 2008). Part II of the UPDRS- activities of daily living is a 
self-assessed score completed by the patient. Filled out through a questionnaire the 
patient judges their own ability to successfully perform certain tasks. These include: 
speech, salivation, handwriting, cutting food, dressing, hygiene, moving in bed and 
altering bed clothes, walking, tremor, and any additional sensory complaints that are 
related to PD. Part III is a clinician scored motor analysis of the patient. The areas a 
physician would rate in each patient are: speech, facial expression, tremor at rest, 
rigidity, finger taps, hand movements, rapid altering movements of hands, leg agility, 
rising from a chair, posture, gait, body bradykinesia and hyperkinesia. For both 
UPDRS II and III the rating is completed on a scale of 0-4. A score of zero indicates 
there is not a problem, whereas a score of 4 would indicate severe impairment of the 
task. 
By choosing to combine scores II+III it demonstrates a broader picture of health of 
the patient from perspectives of the clinician and the patient creating a well-balanced 
score and opinion. There are other sections to the UPDRS, however they are not 
relevant to this meta-analysis in the outcomes and objectives that this analysis 








Secondary outcomes  
The secondary outcome observes the adverse effect dyskinesia and how many 
patients experienced it.  
 
Search methods for identification of studies  
Electronic searches  
All the studies were found online using either PUBMED or Primo.  
Searching other resources  
Studies that were unavailable were requested through the ILL (inter library loan 
system), and suitable studies that matched the criteria were used in the meta-
analysis. 
Data collection and analysis  
In some of the articles UPDRS scores II and III were separate. I chose to combine 
the scores and not enter them as separate entities as I wanted to gain a realistic 
effect of the treatment. UPDRS III was a measurement taken by the clinician 
whereas UPDRS II is a patient evaluation of activities of daily life. By combining the 
scores it gives a broader overview from all perspectives and a true analysis. 
There are two separate primary outcomes in this analysis. Analysis 1.1 (figure 1) is a 
dichotomous outcome; a risk ratio statistical analysis was carried out with fixed 
effects at a 95% confidence interval. Analysis 1.2 (figure 2) is a continuous analysis, 
the standard mean difference was the statistical method used with random effects 
and a confidence interval of 95%. Analysis 1.3 (figure 3) was a dichotomous 
outcome that used the statistical analysis risk difference with fixed effects at a 95% 
confidence interval.  
Selection of studies  
My first point of search was through the University of Plymouths' library search tool 
for journals, PRIMO. From there I accessed PubMed. My first criteria I looked for 
was COMT inhibitors in the treatment of PD. I narrowed my search to focus on the 
drug entacapone. To ensure my meta-analysis was original I searched for the most 
up to date studies I could find. I did this through requesting an inter-library-loan to 
receive journal articles that Plymouth University was not subscribed to. Through this 
method I was able to access the very recent Tolosa 2013 article which was critical to 
my analysis. When searching through journals and as I progressively narrowed my 
search to make it unique, I discarded studies that didn't match my specification, for 
example if they did not contain both UPDRS II and III scores. 
Data extraction and management  
Extracted data included the UPDRS II and III scores, also dyskinesia data in adverse 
effects for both control and placebo. All details of each experiment was recorded in 
the 'characteristics of study' tables and 'risk of bias' tables using the Review 
Manager 5.2 programme. I was careful to research and record every relevant detail 
to each study, including all decimal places and standard deviations. 
Assessment of risk of bias in included studies  
Any potential bias in the studies included in the analysis was recorded in the 'risk of 
bias' tables. Each section to the table covered a different aspect of the study where 
potential bias could occur. It was either rated as 'low, unclear or high risk' and 
relevant evidence to support this was included where required.  





Measures of treatment effect  
I used a number of different statistical assessments to present the data. Analysis 1.1 
used dichotomous data which was analysed using a risk ratio (RR) with fixed effects 
at a 95% confidence interval (CI). The relative risk ratio (RRR) and the number 
needed to treat (NNT) were calculated from the data to provide an absolute measure 
of treatment effect. 
Analysis 1.2 measured a continuous outcome. The mean difference was measured 
and random effects were used at a 95% CI as it weights the studies more evenly 
than fixed effects option. Random effects is more beneficial for smaller studies, 
analysis 1.2 has 2,656 participants making it quite small in number.  
Analysis 1.3 used dichotomous data and examined the RD with fixed effects at a 
95% CI. The NNT and absolute risk reduction were calculated. 
All outcomes were assessed using Rev Man 5.2 at a 95% confidence interval. 
Unit of analysis issues  
All of the studies in this meta-analysis used consistent units throughout. Combined 
UPDRS II+III scores were used in the primary outcome. When the units were not 
already reported as a combined score UPDRS II scores were added to UPDRS III 
scores to create the final outcome measure I would be using. The number of patients 
experiencing dyskinesia side effects was the secondary outcome. This was 
consistent in all papers and was given as a number of patients who experienced this 
side effect. 
Dealing with missing data  
Myllyla 2001 was the only paper with reported unaccounted missing data. This paper 
did not state the baseline UPDRS II+III scores, it only stated the scores at the end of 
the study. I was therefore able to include this study in analysis 1.1 which just 
examined the UPDRS scores at the end of the study. In analysis 1.1 all the UPDRS 
II+III scores at the end of each individual study were compared. However this study 
was excluded from analysis 1.2 as there was no baseline UPDRS scores therefore I 
was unable to calculate an overall change in the study period. 
Other studies reported excluded data, but there were no other cases of missing data 
without explanations. If any data had gone missing as the case in Olanow 2004, it 
was reported in the article. Olanow 2004 explained that those patients whose data 
had been lost were not analysed or included with any results in any aspect, and the 
patient was completed excluded and no partial data was included. 
Assessment of heterogeneity  
I2 is a percentage that describes the variability of an effect to determine if it is due to 
heterogeneity rather than sampling error (due to chance). It is calculated using the 
chi squared statistic and degrees of freedom and is able to quantify inconsistencies 
across the range of studies. In the presence of heterogeneity a random effects 
outcome weighs the studies more equally than a fixed effects analysis. A ‘fixed 
effects analysis’ ignores heterogeneity, in this case as seen in analysis 1.1 and 1.3 
the p value is interpreted instead. The p value for heterogeneity for analysis 1.1 of 
p=0.005 suggests that the observed effect is very unlikely to have arisen purely by 
chance. The P value for heterogeneity for analysis 1.4 of p=0.00003 also suggests 
that the observed effect is very unlikely to have arisen purely by chance. The I2 value 
from analysis 1.2 (figure 2) =74%. When a value is between 50-90% it is thought 




there may be substantial heterogeneity. Heterogeneity can be due to outliers in 1 or 
2 studies that conflict with the other studies. The Tau2 value is also reported in 
random effects analysis, it is an estimate of the variance between studies. In 
analysis 1.2 (figure 2) the tau2=11.0.  
Assessment of reporting biases  
Myllyla (2001) was the only study to display incomplete outcome data (this can be 
seen clearly in Figure 4). Myllyla failed to include the UPDRS scores at the baseline; 
therefore this study was unable to be included in Figure 2 (analysis 1.2). Brooks did 
not state the age of the patients.  
Data synthesis  
I used dichotomous data for analyses 1.1 and 1.3 and continuous data for analysis 
1.3. In analysis 1.1 the RR was calculated of benefit with 95% CI using a fixed effect 
model. Data is said to be significant compared to the control at 95%CI when the RR 
does not include the number 1. 
Analysis 1.3 also used dichotomous data; however it examined the risk difference. 
This describes the actual difference in the observed risk of events between control 
and experimental interventions. This option can be used when considering both likely 
benefits and harms of an intervention. Analysis 1.3 focuses on adverse effects. The 
NNT and the absolute risk reduction were calculated, these figures allow us to 
determine the chance of adverse effects, this would be used by practitioners to 
analyse the risk of the treatment when prescribing the drug. 
Analysis 1.2 measured a continuous outcome. Unlike dichotomous outcomes, 
continuous outcomes are measured both at the beginning of the study (the baseline) 
before the intervention was administered and then at the end of the study. 
Consequently continuous outcomes are expressed as a change in score from 
baseline to the end of study. The mean difference is measured (as opposed to the 
standardized mean difference as that option is used when outcomes are measured 
using different scales and this meta-analysis uses the same scale -UPDRS). 
‘Random effects’ was used as it weights the studies more evenly than fixed effects 
option. Random effects is more beneficial for smaller studies, analysis 1.2 has 2,656 
participants making it quite small in number. 
Calculations that were used: 
 Relative risk ratio (RRR)= 100% * (1-RR) 
 Number needed to treat (NNT)= 1/ ACR* (1-RR), where ACR= the assumed control 
risk 
 Absolute risk reduction was converted to a percentage by multiplying the data by 
1000. 
These additional calculations support the data and help to demonstrate the results 
allowing them to be more easily interpreted by practitioners. 
The weight of each study is important in a meta-analysis and it is vital it is taken into 
account to prevent bias and causing skewed results. In analysis 1.1 the weighting of 
each study does slightly vary, however in analysis 1.2 they are more equally 
weighted with a small variation from 12.1-14.8%. 
Subgroup analysis and investigation of heterogeneity  




This review only looked at one primary outcome and there were no subgroups within 
this analysis. Therefore it was not necessary to perform a meta-regression analysis 
either. Heterogeneity can be determined from the forest plots (as seen in analysis 
1.1, 1.2 and 1.3). The heterogeneity is represented by Chi2 value, P value and I2 
value. These statistics help to gage the heterogeneity of an analysis.  
Sensitivity analysis  
A sensitivity analysis can be carried out when there is suspicion or uncertainty 
whether to include a study in the meta-analysis. However all the studies used in this 
review are randomised and double blind and there are small amounts of bias (this is 
demonstrated in figures 4 and 5) Therefore it was not necessary to perform a full 




Description of studies  
See characteristics of included studies tables. 
A total of 8 studies fulfilled the selection criteria and were analysed in this meta-
analysis with a total of 2,930 patients. 1,578 patients were randomly allocated to 
entacapone treatment and 1,353 were randomly assigned to control/placebo groups. 
All of the studies compared entacapone as an adjunct to levodopa treatment. All of 
the studies were randomised, double-blind and used 200mg of entacapone and 
examined patients with idiopathic PD. The length of the studies ranged from 13 
weeks to 134 weeks with the average length of study approximately 40 weeks. 
All of the studies prohibited previous use of COMT inhibitors. 
Results of the search: included studies  
A total of 8 studies fulfilled the inclusion criteria for this meta-analysis, with a total of 
2930 participants. All of the studies except Brooks 2003, stated the age of the 
participants. Stoccho 2010 participants were aged between 30-70; all of the 
remaining studies used participants between ages 30-80. Every study was 
randomised and double blinded. All studies excluded patients that had any additional 
neurological disorders, such as dementia or any metal disorders . Non-selective 
MAO-inhibitors and any drugs that have dopaminergic action were prohibited in all 
studies. Previous use of COMT inhibitors was not permitted and all levodopa 
treatment had to be stable for at least 4 weeks prior to randomisation. All of the 
studies used the UPDRS for measuring the primary outcome and for the secondary 
outcome- side effect dyskinesia it was measured by the number of participants that 
experienced this effect. 
The DDC inhibitor that is always administered with each levodopa dose was usually 
carbidopa. In some studies benserazide was allowed as an alternative. (Myllyla 
2001), (Poewe 2002; Rinne 1998) 
Dopamine agonists, selegiline, anticholinergics and amantadine were permitted in 
some studies; (Brooks 2003), (Haucer 2009- this study allowed dopamine agonists 
providing they had not been used 30 days prior to the study), (Myllyla 2001; Poewe 
2002; Rinne 1998; Stocchi 2010 (permitted the above stated drugs except 
amantadine which was prohibited)). 




Drugs that were prohibited were: Apomorphone, non-selective MAO-inhibitors and 
any drugs that have dopaminergic action (Brooks 2003; Hauser 2009; Myllyla 2001; 
Olanow 2004; Poewe 2002), 
Brooks 2003:  
A 6 month study of 172 fluctuating PD patients. This study also looked at non-
fluctuating patients which were not included in this meta-analysis. Patients were 
already being treated with levodopa which was stabilized at least 4 weeks prior to 
the study. The experimental group of 115 patients were given 200mg of Entacapone 
with each of their daily levodopa doses. The 57 patients in the control group received 
their regular levodopa treatment and were given a placebo tablet. Apomorphone, 
non-selective MAO-inhibitors and any drugs that have dopaminergic action were 
prohibited. Anti PD drugs that were permitted were: dopamine agonists, selegiline, 
anticholinergics and amantadine. 
Hauser 2009: 
39 week study of 423 patients, some patients were excluded before randomisation 
making a total number of 392 patients. 177 patients were assigned to the 
experimental treatment and 215 were in the control group. 200mg of entacapone 
was administered to the experimental group in a combined pill which also contained 
the patients’ regular levodopa treatment. The control group also received 1 pill that 
contained only their regular levodopa treatment. This study permitted the use of co-
enzyme Q10, there was no mention of this co-enzyme in any of the other studies. 
Myllyla 2001: 
12 month study of 326 PD patients. 218 patients were randomised to experimental 
treatment and 108 to control. A 200mg entacapone tablet of identical placebo was 
administered with every levodopa dose. The DDC inhibitor that was administered 
with levodopa was either benserazide or carbidopa. Patients that had been treated 
with reserine or apomorphine within 6 months prior to randomisation were excluded 
from the study. This study permitted the standard or controlled release of levodopa 
and included fluctuating and non fluctuating patients. 
Olanow 2004: 
26 week study of 862 patients, however 112 were excluded before treatment 
allocation. Therefore 373 patients were randomly allocated to entacapone treatment 
and 377 were randomly allocated to the placebo treatment group. 200mg of 
entacapone or matching placebo was administered with every levodopa dose. Other 
antiparkinsonian drugs were permitted if they were stable for 1 month before study 
entry, but the individual specific drugs allowed were not stated. 
Poewe 2002: 
7 month study of 301 PD patients. 197 were randomly assigned to the entacapone 
treatment and 104 were assigned to the placebo treatment group. 200mg or placebo 
were administered with every levodopa dose. Controlled and immediate release 
preparations were permitted. The DDC inhibitor could either be carbidopa or 
benserazide. The primary outcome of this study was measuring proportion of daily 
'on/off' time that can be experienced when taking PD medication. The secondary 
outcome measured UPDRS scores. 
Rinne 1998: 
24 week study of 171 patients. 85 patients were randomly assigned to entacapone 
treatment and 86 were assigned to the placebo treatment. Patients either took 




200mg entacapone or identical placebo with each levodopa dose. Patients were able 
to take either carbidopa or benserazide as the DDC inhibitor. Controlled release 
levodopa was not permitted. Any additional anti PD medication had to be stable for 
at least 4 weeks before randomisation. 
Stocchi 2010: 
134 week study of 745 patients. 373 were randomised to the 200mg entacapone 
treatment group, 372 were assigned to the placebo group. Patients either took 
200mg of entacapone with every levodopa dose or just levodopa. Each treatment 
group was administered in 1 combined pill. Previous use of COMT inhibitors was 
prohibited. Patients could not have taken amantadine within the preceding 270 days 
due to its anti-dyskinesia effects. 
Tolosa 2013: 
3 month study of 96 patients. 46 were randomised to 200mg entacapone 
(experimental group) and 49 patients were randomly assigned to the placebo group 
that received levodopa/carbidopa treatment with no entacapone. Both treatments 
were administered in 1 pill to eliminate chances of bias and to prevent un-blinding of 
the treatment groups. Previous use of COMT inhibitors was prohibited as was: any 
participants with a history of atypical or secondary parkinsonism, psychiatric 
disorders, dopaminergic treatments, patients with depression, treatment with 
neuroleptics, rotigotine or MAO inhibitors. This study examined immediate and slow 
release levodopa, I will only be using the data from the immediate release patients. 
Excluded studies  
The main reason for the exclusion of some studies was because they didn't include 
all of the relevant data that was required upon further inspection of the articles. (See 
characteristics of excluded studies for more detail). 
Bet (2008) used the UPDRS as the primary outcome, however the study only 
analysed UPDRS III and did not include any data for UPDRS II therefore this study 
could not be included in my review as both UPDRS II+III were required to create an 
overall view from clinician and patients viewpoint. If this study was included it would 
cause potential bias towards the clinicians viewpoint and motor score rating because 
the patients self-assessment (UPDRS II was not reported). This was also true for 
Piccini (2000), and for Kieburtz (1997) only UPDRS II was measured and not 
UPDRS III 
Durif (2001) was conducted as an open study, part of the specific criteria of this 
review ensured that the trials included were placebo controlled and double blinded to 
ensure bias is kept to a minimum where possible. Furthermore there was no control 
or placebo used in this study consequently there would be no baseline to compare 
results to. Gershanik (2003) also only had data for the experimental group of 
entacapone treatment with no control or placebo treatment group. 
Larsen (2003) appeared to fit the selection criteria, however on further reading of the 
paper it became apparent that it was a follow up study to a trial that is already been 
included in this meta-analysis (Rinne 1998). Therefore this study was not needed in 
addition. Mizuno (2007) primary outcomes focused mainly on 'on/off time' of the 
treatment and didn't include enough data required for UPDRS for this analysis. 
Olanow (2013) was a review article of previous studies and did not contain any 
primary data, therefore was excluded. Reichmann (2005) did not use UPDRS as the 




primary outcome, the study didn't include all of the standard deviations and data for 
the UPDRS scores that was required for this meta-analysis.  
 
Risk of bias in included studies 
All of the studies were randomised, the method for most of them was by randomised 
computer generation; however some of the studies did not state their randomisation 
methods.  
Allocation (selection bias)  
All of the studies used random allocation. Brooks (2003) carried out randomisation 
by the department of biostatistics of Orion Pharma, using a computerised method. 
Olanow (2004) used a computer generated randomised schedule to allocate 
participants to their treatment groups. Poewe (2002) used a computer generated 
randomisation procedure in a ratio of 2:1. Stocchi (2010) used a computer generated 
randomisation sequence to allocate participants to treatment groups. Tolosa (2013) 
used a randomised sequencing programme SAS version 9.1 statistical software, with 
random block sizes of 4. 
Hauser (2009), Myllyla (2001) did not state the method they used to carry out 
randomisation, only that they were allocated randomly to treatment groups. Although 
the allocation concealment was definitely stated as random for Hauser (2009) and 
Myllyla (2001) the method is not stated and is therefore unknown. Consequently we 
cannot be entirely sure of the risk and on Figures 4 and 5 these 2 studies are 
highlighted in yellow as an 'unclear risk'.  
 
 
Figure 4: Risk of bias graph: review authors' judgements about each risk of bias 


















Figure 5: Risk of bias summary: review authors' judgements about each risk of bias 
item for each included study. 
 
 
Blinding (performance bias and detection bias)  
All studies included in the meta-analysis were double blind to help reduce any forms 
of bias where possible. 
Incomplete outcome data (attrition bias)  
In all of the studies there were patients that did not complete the whole duration of 
the trial. In all cases the reason for withdrawal was explained. The main reason for 
withdrawal from the study was due to adverse effects. In some of the studies there 
were reported deaths of the patients, although in every case none were thought to 
be related to the study medication  




Selective reporting (reporting bias)  
For each of the 8 studies that are included in this meta-analysis a careful comparison 
was made between the primary objectives and the primary outcomes to ensure that 
the study reported what it set out to achieve. All of the 8 included studies reported 
the outcomes they had aimed to meet.  
 
Other potential sources of bias  
The Myllyla 2001 and Poewe studies permitted controlled and standard release 
levodopa. It also permitted fluctuating and non fluctuating patients. This may have 
caused potential bias as other studies did not permit these things. Both these studies 
permitted both carbidopa and benseraide as the DDC inhibitor. Other studies only 
allowed carbidopa. 
A further potential source of bias could be due to finances. In many of the studies it 
does not state who funded the study. However the study by Stocchi 2010 was 
funded by Orion Pharma, this is also the company that manufactures the drugs being 
tested. Furthermore the authors of the paper have served as consultants to Orion. 
This raises the question to how reliable is this study, is this an unfair trial if it is the 
drug company themselves that is testing their own drug. They know what outcome 
they want to portray for their drug, why did they not use an independent unbiased 
outsource company to test the drug for them.  
Financial gain can often be found at the heart of the pharmaceutical industry and it 
becomes increasingly difficult to judge validity of results. After all, it has been 
reported by Ben Goldacre (2012) in the book 'Bad Pharma' that very often drugs are 
tested by the people who manufacture them, often on unrepresentative patients, 
using techniques that may have been flawed by design in such a way that they 
exaggerate the benefits of treatments which then lead to results that favour the 
manufacture. It has also been shown that drug companies are more than entitles to 
abandon and hide results of trails from doctor and patients that the companies don't 
like; potentially producing a distorted image of any drug's true effects. Obviously this 
is not always or often the case, however it raises a thought of how often this may 
happen in this industry and is up to us as an independent opinion to carefully 
scrutinise the evidence that is available to make informed conclusions and decisions. 
  
Effects of interventions  
All 3 of the outcomes of this intervention analysed different comparisons based on 

















Figure 1 (Analysis 1.1): Forest plot of comparison: 1 Levodopa/DDCI/Entacapone versus 
Levodopa/DDCI/Placebo, outcome: 1.1 UPDRS II + III. 
 
Figure 1 (Analysis 1.1) is a dichotomous analysis that compares 
levodopa+DDCI+entacapone versus levodopa+DDCI using a risk ratio (RR) with 
fixed effects at a 95% confidence interval (CI). The risk ratio is 0.76 with CI of 0.66-
0.88. RR's describe the multiplication of the risk that occurs with use of the 
experimental intervention. 
Poewe 2002, Brooks 2003 and Myllyla 2001 all strongly favour the experimental 
treatment, with RR's between 0.46-0.53, all 3 of these studies CI all favour the 
entacapone treatment also. Rinne 1998, Tolosa 2013 and Olanow 2004 also have 
RR that favour the experimental treatment, just not as strongly. Their RR range from 
0.81- 0.98. Their CI all cross over into favouring the control. Stocchi 2010 and 
Hauser 2009 both slightly favoured the control with RR of 1.05 and 1.06, they also 




Figure 2 (Analysis 1.2): Forest plot of comparison: 1 Levodopa/DDCI/Entacapone versus 
Levodopa/DDCI/Placebo, outcome: 1.2 Change in UPDRS scores (II+III) from baseline to 
finish. 




Figure 2 (Analysis 1.2) is a continuous outcome that examines the change in 
UPDRS scores II+III from baseline to finish. This analysis uses the statistical method 
mean difference with random effects at a 95% CI. Mean difference is used to give 
the absolute difference between the mean value of 2 groups. The standardized 
mean difference would be used if the outcomes were measured using different 
scales, however in this analysis all outcomes were measured using UPDRS II+III. By 
examining the change in UPDRS II+III scores from baseline to the end of each study 
this gives an overall score for improvement in the patients and reflects the success 
of each study. The total mean difference score for analysis 1.2 = -2.15 with CI= -
4.66, 0.36. This indicates the average change in UPDRS was -2.15 which favours 
the experimental entacapone treatment. However it has large confidence intervals 
that slightly cross over 0 into favouring the control. 
Rinne 1998 most favours the experimental treatment with an average mean 
difference of -8.50. This study had very small CI of -8.78,-8.22 therefore making the 
interval bars on the forest plot barely visible. Tolosa 2013, Poewe 2002, and Olanow 
2004 also all completely favoured the experimental treatment. With mean difference 
scores of -4.60, -4.30 and -0.50. All of the CI also favoured the experimental 
treatment. Brooks 2003 had a mean difference of 0.4 which slightly favoured the 
control treatment. Stocchi 2010 and Hauser 2009 both favoured the control 
treatment with mean difference values of 1.20 and 1.50. However both of their upper 
CI did slightly favour the experimental treatment. 
 
 
Figure 3 (Analysis 1.3): Forest plot of comparison: 1 Levodopa/DDCI/Entacapone versus 
Levodopa/DDCI/Placebo, outcome: 1.4 Adverse Effects- Dyskinesia. 
 
Figure 3 (Analysis 1.3) is a continuous outcome that uses the statistical method 
mean difference (RD) with fixed effects at a 95% CI. Figure 3 analyses the side 
effect dyskinesia and compared the results of the experimental and control groups. 
RD explains the estimated difference in the probability of an individual experiencing 
an event- in this case the adverse effect. The average RD is 0.05 which indicates 
slight favour of the control group, with CI 0.03, 0.07. Hauser 2009 was the only study 
that favoured the experimental group, although this was by a very tiny amount of -
0.02. all other studies favoured the control group. This is as expected and will be 
explored more in the discussion section. 




From this analysis we could therefore reject the null hypothesis and conclude that 
the entacapone treatment does improve combined UPDRS scores II+III. 
 
Discussion  
Summary of main results  
This review included 8 studies comparing entacapone 200mg as an adjunct to 
levodopa+DDCI therapy. Patients used their standard dose of levodopa+DDCI in 
both the experimental and control groups. Combined UPDRS scores II+III were the 
primary outcome this review focused on. The secondary outcome examined the 
adverse effect dyskinesia. 
Figure 1(Analysis 1.1) is a dichotomous outcome that examined all 8 studies with a 
total number of 2930 participants. 1578 were in the experimental group and 1352 
participants were in the control group. The RR=0.76 CI [0.66,0.88]. The relatively 
small CI suggests the effect size is known precisely. The RR can be re-expressed as 
a relative risk ratio (RRR) by= 100% *(1-RR). The RRR for analysis 1.1 is 24%. This 
can be interpreted as the entacapone experimental treatment decreases the risk of 
events my 24%. In the summary of results table it states the risk per 1000 patients. 
From this I was able to calculate the number needed to treat (NNT) of patients. For 
the study population, the assumed control risk was 207/1000, for the corresponding 
risk (entacapone) it was 157/1000. I was then able to calculate NNT by the following 
equation: 
NNT= 1/ ACR*(1-RR), when the data for this analysis was entered: NNT= 
1/0.207*24, NNT=12.29, which would be rounded to 13 (NNT is always rounded up). 
This can be interpreted that it is expected that one additional (or less) person will 
incur a reduction in UPDRS score for every 12 participants receiving the entacapone 
as an adjunctive treatment to levodopa+DDCI as opposed to the placebo (control 
treatment) over a given time frame (the studies ranged from 3-12 months). The P 
value for overall effect P=0.0001, therefore suggesting that the observed effect is 
very unlikely to have arisen purely by chance and provides evidence against the null 
hypothesis. From which we can interpret that entacapone treatment is preferable 
compared to placebo. 
Figure 2 (Analysis 1.2) is a continuous outcome that examined 7 out of the 8 studies 
with a total of 2656 participants. 1369 belonged to the experimental treatment group 
and 1260 were in the control group. The mean difference for this analysis is -2.15 
with CI [-4.66,0.36] The mean difference favours the experimental treatment group, 
however it has a wide CI. The outcome was measured using the same scale of 
change in UPDRS scores II+III from baseline to end of study. Consequently a pooled 
estimate was generated that can be seen in the summary of results table. There is a 
range of -6.1 to 10 in UPDRS II+III score differences over the studies that were 
between 3-12 months. On average the UPDRS II+III scores decreased by 2.15 
points, this favours the entacapone treatment compared to placebo treatment as a 
lower score indicates an improvement in the patient. The summary of results table 
also suggests 'high grade' this indicated good quality data as all the studies were 
double blinded, randomised and placebo controlled. The P value for overall effect 
P=0.09, therefore this suggests there is not strong evidence that the intervention has 
an effect. 




Figure 3 (Analysis 1.3) is a dichotomous outcome that examined all 8 of the studies 
with a total number of 2930 participants. 578 were in the experimental group and 
1352 participants were in the control group. The risk difference (RD) was calculated 
in order to determine the probability of an individual experiencing the adverse effect 
dyskinesia in the experimental group compared to the control group. The RD= 0.05 
[with CI=0.03-0.07]. The RD can be expressed as an absolute risk reduction, which 
is therefore 5%. The NNT can also be calculated by a slightly different method 
compared to RR. For RD NNT= 1/absolute value of risk difference, therefore 
1/0.05=20 participants needed to treat. This can be interpreted that 1 participant will 
incur the adverse effect dyskinesia for every 20 participants, when receiving 
entacapone treatment as an adjunctive treatment to levodopa+DDCI as opposed to 
the placebo (control treatment) over a given time frame (the studies ranged from 3-
12 months). The P value for the test of overall effect P=<0.0001, this would suggest 
that the observed effect is very unlikely to have arisen purely by chance and 
provides evidence against the null hypothesis. 
The risk of bias graph (Figure 4) demonstrates how every study was double blinded, 
this helps to remove any potential bias with patients guessing which treatment group 
they are in. Generally there is a low amount of bias throughout all of the meta-
analysis. 
Figure 4 demonstrates a graph highlighting the sources of potential bias in each 
individual study. From this figure is raises slight concern about Myllyla 2001 study 
which contains the most bias. 
Overall completeness and applicability of evidence  
All of the studies were completed and the quality of evidence is moderate to high. 
This is supported by the risk of bias figures (4 and 5) and further demonstrated in the 
summary of results table which categorised the grade of data as 'high' for every 
outcome. The table also states moderate quality, which can be interpreted as: 
Further research is likely to have an important impact on our confidence in the 
estimate of effect and may change the estimate.  
Quality of the evidence  
The quality of the evidence in this meta-analysis is reasonably high, all the studies fit 
the criteria and have a good number of participants in each study to produce a well-
balanced and reliable result. There are also relatively low levels of bias; this is shown 
in figures 4 and 5.  
Potential biases in the review process  
There is some potential biases in this review which may have had repercussions on 
the results and could explain the result seen in analysis 1.1. Myllyla 2001, Poewe 
2002, Rinne 1998 all permitted an alternative DDC inhibitor, benserazide, in addition 
to carbidopa. Carbidopa in the only DDCI allowed in the other studies. The patients 
were assigned either DDCI according to the choice of the clinician based on previous 
levodopa treatment. However it is unlikely this caused bias considering that Rinne 
1998 demonstrated results that significantly favoured entacapone treatment 
compared to control in analysis 1.1 and 1.2. 
Other sources of bias could be the use of control release or immediate release 
levodopa. This was the case in Brooks 2003 and Poewe 2002. A potential source of 
bias that may explain why Myllyla consistently produced results that favoured the 
control treatment could be the allowance of fluctuating and non fluctuating patients in 




the study, the rest of the studies used fluctuating patients. I still chose to include 
Myllya 2001 in the meta-analysis as it fitted the selection criteria and complied with 
all the other variables. It is also a case that may be seen in real practise. 
Hauser 2009 produced results in analysis 1.1 and 1.2 that favoured the control 
treatment. One potential source of bias from this study could have been the use of 
coenzyme Q10, this was permitted in this study whereas in every other study in the 
meta-analysis Q10 was not mentioned. Another factor that may have caused bias in 
the study was the uneven gender distribution across the experimental and control 
groups. The experimenters acknowledged this and performed an additional analysis 
that incorporated gender into the model as a primary efficacy variable. The study 
then produced at p value of 0.023 which favoured the entacapone treatment group. 
Compared to analysis 1.1 where the average mean difference was 0.06 95% CI(-
0.14, 0.25) and in analysis 1.2 an average standard mean difference of 0.14 95% 
CI(0.27,0.75). However in this additional analysis the experimenters did not report all 
the individual data values required to tabulate them in this review to create a new 
analysis. If this data was available the new analysis may have produced different 
conclusions favouring the entacapone treatment more. 
UPDRS II is a self-assessed patient rating on activities of daily life. Even though 
there is a detailed questionnaire to guide the patient combined with thorough 
descriptions to help them categorise and determine their rating of a specific task 
there will always be slight discretions and inconsistencies that vary between patients 
own opinions of their ability to execute a given task. Therefore leaving a potential to 
bias, some patients may over or underestimate their capabilities. However this is 
why the UPDRS II and III scores are combined to given an overall rating. This will 
help to remove patient derived bias as the clinicians should be assessing patients 
UPDRS III scores with the same criteria and will be more experienced in analysing 
patients therefore producing consistent ratings as opposed to a patient themselves. 
Nevertheless it is good to get a fair and balanced viewpoint for the patient and 
clinician which is the aim of this meta-analysis.  
Agreements and disagreements with other studies or reviews  
The most previous meta-analysis that examined COMT inhibitors as potential 
adjuncts to levodopa therapy was from 2010, however the most recent study it 
included in the analysis was from 2004. This meta-analysis had a primary outcome 
of UPDRS II and UPDRS III but they were separate outcomes. They did include an 
outcome that looked at total UPDRS scores however this included UPRDRS 
I,II,III,IV,V. In the individual UPRDS II and III scores they concluded that entacapone 
treatment was preferable, and therefore agreeing with the updated conclusions of 
this meta-analysis.  
 
Authors' conclusions  
Implications for practice  
Entacapone is generally a well-tolerated drug and is an effective adjunct to levodopa 
treatment, dyskinesia is more common in entacapone compared to placebo, but not 
significantly and when compared to the benefits of entacapone treatment clinicians 
would most probably recommend the entacapone treatment as an adjunct to 
levodopa+DDCI therapy as the risk of dyskinesia is minimal. 
 




Implications for research  
More research needs to be done in this area to confirm the results. When more 
studies are carried out under the same conditions and new meta-analysis could be 
created to hopefully confirm the findings of this review, it would have the potential to 
be more significant and reliable if more participants are involved and if there is a 
greater number of studies available. Future research will look at drugs to stop the 
prevention of further depletion of the dopaminergic neurons and potentially reverse 
the damage, 
At present, only symptomatic treatment exists and nothing can be done to halt the 
degenerative process, as its cause remains unclear. 
Technology within science is rapidly evolving, nanotechnology is novel technology 
that helps to overcome some of the current problems that levodopa therapy currently 
faces. For example a major limitation to levodopa therapy is the minimal amount that 
can react to the CNS via the blood brain barrier (BBB). The BBB enables the 
passage of small lipophilic, large hydrophobic or charged particles that require 
facilitated transport. The CNS restricts the entry of dopamine because it is a polar 
compound. With the help of nanotechnology it would enable the packaging and 
transport of small molecules across the BBB in order to target specific structures, 
which would avoid degradation in the plasma and reduce systemic side effects 
(Linazasoro 2008) This therapy is still a far distance away, but in the future it may aid 
the pharmacological treatment of Parkinson's disease. 
 
Characteristics of studies  
 
Characteristics of included studies  
Brooks 2003  Table 1.0 
Methods Randomised: Yes, patients were separated into fluctuating and 
non fluctuating and then randomly assigned within these two 
groups into the treatment groups. The randomisation was 
carried out by the department of biostatistics of Orion Pharma, 
using a computerised method. 
Blinded: Double blind, placebo controlled 
Treatment period: 6 months 
Participants Eligibility: Patients were recruited from 29 neurology and 
movement disorder clinics from the UK and the Republic of 
Ireland. All patients were being treated already with levodopa, 
patients medication had to have remained stable for at least 4 
weeks before randomisation. All patients were treated with 
either standard formulation of controlled release levodopa. Anti 
PD drugs that were permitted were: dopamine agonists, 
selegiline, anticholinergics, amantadine. 
Exclusion criteria: Apomorphine, atypical PD,dementia and 
other neurological disorders were excluded. Non-selective 
MAO-inhibitors and any drugs that have dopaminergic action 
were prohibited in the study.  
Number of participants:172 fluctuating patients and 128 non 





Distribution to treatment: 115 fluctuating patients were 
assigned to Entacapone and 57 were randomly assigned to 
placebo. 
Interventions 200mg of Entacapone was administered with each daily 
Levodopa dose, or placebo was administered with the daily 
Levodopa treatment.  
Outcomes Primary: Proportion of daily 'on time' compared to baseline and 
placebo 
Secondary: UPDRS I,II and III, adverse effects. 
Notes This study looked at fluctuating and non fluctuating patients, I 
will only be using the data from the fluctuating patients. 
 








Low risk Randomisation was carried out by the 
department of biostatistics of Orion 















Incomplete outcome data 
(attrition bias) 
Low risk 




All outcomes were reported 
Other bias Low risk 
 
 
Hauser 2009 Table 1.2 
Methods Randomised: Yes (Method not stated) 
Blinded: Double Blind, parallel group, multicentre study at 53 
centres in Canada, Czech Republic, Israel, Italy, Poland, 
Portugal, Turkey and USA. 
Treatment period: 39 Weeks 
Participants Eligibility: Patients with PD that had at least two out of three 
cardinal signs (bradykinesia, rigidity and rest tremor). Patients 
were between ages 30-80 years at diagnosis. Patients were 
permitted to use amantadine, anticholinergics, selegiline, 




rasagiline, and coenzyme Q10 providing they were a stable 
dosages at least 30 days prior to baseline. 
Exclusion criteria: Previous use of COMT inhibitor and use of 
dopamine agonists for more than 30 days or within 4 weeks 
prior to baseline were excluded. Patients with 
atypical/secondary parkinsonism, patients prior to 
neurosurgery and patients with other neurological conditions or 
mental disorders were not included in the study. 
Number of participants: 423 
Distribution to treatment: 208 patients were given 
Levodopa/Carbidopa/Entacapone and there were 215 patients 
in the Levodopa/Carbidopa treatment group. 177 patients in 
the entacapone group completed the study, 190 in the control 
group completed. Entacapone treatment was a 200mg dose. 
Interventions Patients were randomly assigned to either 
entacapone/levodopa/DDC inhibitor(carbidopa) or 
levodopa/DDC Inhibitor (carbidopa)  
Outcomes Primary: UPDRS II and III scores 
Secondary: Hoehn-Yahr stage and Schwab and England ADL 
score 
Notes There was no placebo administered in the levodopa/carbidopa 
group, however only 1 pill was administered in each group and 
the trial was double blind therefore patients had no way of 
knowing which test group they belonged to.  
 













Unclear risk Although the allocation concealment was 
definitely stated as random the method not 
stated and is therefore unknown. 
Consequently we cannot be entirely sure of 
the risk. 











data (attrition bias) 
Low risk Data was complete, where participants did not 
complete the trial it was stated reasons why, 
and only complete data was used in the 








study reports all outcomes 
Other bias High risk Coenzyme Q10 was permitted and this was 
not mentioned in any other studies. 
 
Myllylä 2001 Table 1.4 
Methods Randomised: Yes (method not stated). 
Blinded: Double-blind, placebo controlled, parallel-group 
design. 
Treatment period: 12 months 
Participants Eligibility: 'typical PD outpatients patients' levodopa-
responsive, idiopathic PD that needed enhancement and or 
smoothening of Levodopa effects. Carbidopa and benserazide 
were permitted as the DDC inhibitor. 
Exclusion criteria: Patients with secondary Parkinsonism, 
dementia or any other significant neurological disease were 
excluded. Patients with any psychiatric disorders, such as 
depression, were also excluded. Subjects that had been 
treated with neuroleptic agents, a-methyldopa, reserine or 
apomorphie within the last 6 months were excluded as well 
patients that had been treated with either MAO-A inhibitors and 
non-selective MAO-inhibitors within the last month. Levodopa 
treated had to be stable for at least 4 weeks prior to 
randomisation. 
Number of participants: 326, 217 men and 109 women aged 
between 30-80. 
Distribution to treatment: Two-thirds of patients (218) were 
randomised to entacapone and one third (108) to placebo 
treatment. However 51 patients discontinued, the number of 
patients that completed the Entacapone treatment was 182 
and 93 patients completed the treatment in the placebo group. 
Interventions An entacapone 200mg tablet or identical placebo was given 
with each scheduled levodopa/ddc inhibitor dose. the number 
of daily doses ranged from 2 to 10.  
Outcomes UPDRS:  
Mentation, behaviour and mood (part 1) 
ADL (part 2) 
Motor Score (part 3) 
Total score (part 1,2 and 3)  
Side Effects 
Notes The study permitted standard and controlled release of 
levodopa and soluble levodopa preparations and included 
fluctuating and non-fluctuating patients.  
 
 












Low risk It states that patients were randomised to 
treatment groups but does not specifically 




Unclear risk Although the allocation concealment was 
definitely stated as random the method not 
stated and is therefore unknown. 
Consequently we cannot be entirely sure of 
the risk. 











data (attrition bias) 
High risk Missing data, study does not report the 
baseline UPDRS scores and only states the 
end scores. Therefore an overall change 




Outcomes were all reported 
Other bias High risk Study permitted the use of an alternative 
DDCI, patients could either use carbidopa or 
benserazide. The study also permitted 
fluctuating and non fluctuating patients.  
 
Olanow 2004 Table 1.6 
Methods Randomised: Yes, method: computer-generated randomised 
schedule 
Blinded: Double-blind, placebo-controlled, parallel group study  
Treatment period: 26 weeks 
Participants Eligibility: Male and female participants with idiopathic PD over 
age 30. Diagnosis of PD based on good response to Levodopa 
and at least two of the following: rigidity, resting tremor and 
bradykinesia. Other anti-parkinsonian medications were 
permitted providing the dose was stable for 1 month before the 
study entry. 
Exclusion criteria: Previous exposure to COMT inhibitors, 
secondary or atypical parkinsonism, medical or psychiatric 
illnesses and any other neurological disorders were prohibited 
in the study. 
Number of participants: 862 
Distribution to treatment: 373 allocated to 




Entacapone/Levodopa/Carbidopa, 377 allocated to 
Levodopa/Carbidopa/Placebo. (112 patients were excluded 
before patients were allocated groups, making the total number 
of participants 750. 
Interventions 200mg of Entacapone or matching placebo was administered 
with every dose of Levodopa.  
Outcomes Primary: Changes in UPDRS III 
Secondary: UPDRS II 
Notes The dose of levodopa/carbidopa could not increase during the 
study and the levodopa/carbidopa could not switch 
formulations. It could however be decreased, any drug 
adjustments were performed by a blinded treatment 
investigator. 
 




Support for judgement 
Random sequence generation 
(selection bias) 




Low risk computer-generated randomised 
schedule 
Blinding of participants and 
personnel (performance bias) 
Low risk 
Double-blind trial 
Blinding of outcome 
assessment (detection bias) 
Low risk 
Double-blind trial 




Selective reporting (reporting 
bias) 
Low risk Study measures and records its 
outcomes that it states in its 
objectives.  
Other bias Low risk 
 
 
Poewe 2002 Table 1.8 
Methods Randomised: Yes, in a ratio of 2:1 by a computer generated 
randomisation procedure. Patients were from 30 centres in 
Germany and Austria. 
Blinded: Double blind, parallel group study. 
Treatment Period: 7 months 
Participants Eligibility: The study allowed a wide range of PD patients in 
order to gain more experience on the use of entacapone. 
Eligible patients may have had less advanced PD, patients 
without obvious motor fluctuations were also allowed. Use of 2-
10 daily doses of standard or controlled release levodopa 




preparations. Additional PD drugs that were permitted were: 
amantadine, memantine, anticholinergics, selegiline and 
dopamine agonists. 
Inclusion Criteria: Patients were Levodopa responsive with 
idiopathic PD, aged between 30-80 and required enhancement 
or smoothening from the effects of Levodopa. Levodopa 
treatment had to be stable for at least 1 month before the study 
began. 
Exclusion Criteria: Treatment with neuroleptics, antiemetics, 
catechol structured drugs, MAO-inhibitors and non-selective 
MAO inhibitors were prohibited. Patients with other major 
neurological, psychiatric or medical disorders were excluded.  
Number of Participants: 301 
Distribution to treatment: 197 patients were randomly assigned 
to entacapone treatment and 104 patients were assigned to the 
placebo treatment. 
Interventions Entacapone 200mg or placebo was administered with the 
patient’s standard levodopa/DDCI treatment. 
Outcomes Primary: Proportion of daily 'on and off time' recorded by the 
patient as a home diary.  
Secondary: UPDRS scores (I,II and III) 
Notes Controlled release and immediate release were permitted. 
Most studies have only used immediate release and only 
carbidopa not benserazide, however I have chosen to still 
include this study as all the other variables are maintained and 
also in the everyday life setting looking at typical PD patients 
there will always be slight variations within medications, this is 
because each individual has different needs and may have a 
preference with their existing medication. This study permitted 
the use of other antiparkinsonian drugs, this is to mimic current 
clinical practice as much as possible. The entacapone dose is 
200mg (as identical to all the other articles) and it is compared 
against placebo and is double blind, therefore reducing the risk 
of bias. 
 













Low risk Only the sponsor-employed person who generated 
the plan was aware of a given individuals 




















Low risk There was no instance that required unblinding of 
the assignment during the study, however during a 
post-study visit one of the investigators had to 
open one envelope because the patient had 
diarrhoea and his family doctor insisted on knowing 
the medication. The independent safety monitoring 
committee identified no safety concerns and had 
no reason to either break the code of terminate the 
study prematurely.  
Selective reporting 
(reporting bias) 
Low risk The primary outcome measuring 'on/off time' by 
method of patients home diary was originally 
measuring both 'observed case' and 'last 
observation carried forward' (LOCF), however due 
to a considerable amount of missing recording OC 
was the only outcome analysed. However there 
were no reported problems with the UPDRS scores 
which is the outcome I am interested in.  
Other bias High risk Controlled release and immediate release 
levodopa were permitted in this study, also the 
DDCI used was either benserazide or carbidopa. 
 
Rinne 1998 Table 2.0 
Methods Randomised: Yes (method not stated) 
Blinding: Double blind, conducted in 16 neurologic departments 
in the Nordic countries 
Treatment period: 24 weeks 
Participants Eligibility: Levodopa responsive with idiopathic PD that were 
experiencing motor fluctuations. Patients treated with 
amantadine, anticholinergics, selegiline, or dopamine agonists 
were permitted. Any anti-parkinsonian drugs had to be stable 
for at least 4 weeks before randomisation 
Number of participants: 171 
Exclusion criteria: Control release levodopa was not permitted. 
Distribution to treatment: 85 patients were allocated to the 
Entacapone group and 86 to the placebo group. 152 patients 
completed the study, 77 from the entacapone group and 75 in 
the placebo group. 
Interventions Patients either took 200mg Entacapone or identical placebo 
with each daily Levodopa/DDC inhibitor dose.  
Outcomes Primary: Mean daily 'on and off' times, measured from home 





Secondary: UPDRS I, II, III 
Notes Patients were could either take carbidopa or benserazide as 
their DDC inhibitor with Levodopa.  
 




Support for judgement 
Random sequence generation 
(selection bias) 
Low risk 
Randomised but not stated how. 
Allocation concealment (selection 
bias) 
Low risk 
Randomised but not stated how. 
Blinding of participants and 
personnel (performance bias) 
Low risk 
Double-blind trial 








Selective reporting (reporting 
bias) 
Low risk Study reports all of its 
objectives. 
Other bias Unclear risk Benserazide preparations of 
levodopa were permitted. 
 
Stocchi 2010 Table 2.2 
Methods Randomised: Yes, using computer generated randomisation 
sequence. 
Blinded: Double blind, Multicentre study; patients were from 77 
centres in 14 countries in Europe and North America. 
Treatment period: 134 weeks 
Participants Eligibility: Men or women aged 30-70 with a diagnosis of PD 
based on UK brain bank criteria and a disease duration of <5 
years from time of diagnosis. 
Exclusion Criteria: Patients were excluded if they had taken 
amantadine within the preceding 270 days. Previous use of 
COMT inhibitors was not permitted. Patients with secondary 
parkinsonism, concomitant use of neuroleptic agents and any 
medical and psychiatric conditions were excluded from the 
study. 
Number of participants: 745 
Distribution to treatment: 373 patients were in the entacapone 
group and 372 in the placebo group. However 541 patients 
completed the study, 265 in the entacapone group and 276 in 
the control group. Withdrawal was mainly due to adverse 




effects and unsatisfactory therapeutic effect. 
Interventions Participants were randomised to either 200mg entacapone with 
every levodopa/DDC inhibitor dose or just levodopa/DDC 
inhibitor. The DDC inhibitor used was carbidopa. There was no 
placebo pill given, but both treatment groups were given their 
medication in 1 pill, and as the study was double blind there 
was no way of knowing which treatment group the patient was 
in 
Outcomes Primary Outcome: Time to onset of dyskinesia. 
Secondary Outcome: Frequency of dyskinesia, change from 
baseline in total UPDRS parts II and III, time and frequency of 
wearing off episodes. 
Notes Patients were allowed to be taking stable doses of a dopamine 
agonist or other antiparkinson's medications as long as it had 
been stable for at least 4 weeks previous to the trial. They 
could not have taken amantadine within the preceding 270 
days due to its anti-dyskinesia effects.  
 




Support for judgement 
Random sequence generation 
(selection bias) 
Low risk computer generated 
randomisation sequence 




Blinding of participants and 
personnel (performance bias) 
Low risk 
Double-blind trial 








Selective reporting (reporting bias) Low risk All outcomes are reported. 
Other bias Low risk 
 
 
Tolosa 2013 Table 2.4 
Methods Randomised: Yes, using randomised sequencing programme 
SAS version 9.1 statistical software, using random block sizes 
4. 
Blinding: Double-blind, multicentre, parallel-group study.  
Treatment Period: 3 months 
Participants Eligibility: Patients were male and female between ages 30-80 
and had idiopathic PD as diagnosed by the UK Parkinson's 
Disease society brain bank criteria, patients had to be stable 




on Levodopa treatment for at least 1 month before the study. 
Patients had mild or minimally disabling motor complications. 
Patients were permitted to have used selegiline or rasagiline, 
providing treatment was stable for at least 60 days prior to the 
screening visit.  
Exclusion criteria: Patients who had previously or were 
currently being treated with entacapone, symptoms or a history 
with atypical or secondary Parkinsonism, hallucinations or 
psychiatric disorders related to dopaminergic treatments, major 
depression, treatment with neuroleptics, rotigotine or 
monoaminooxidase inhibitors .  
Number of Participants: 96 
Distribution to treatment: 46 patients were randomly assigned 
to treatment Levodopa/Carbidopa/Entacapone and 49 patients 
were randomly assigned to Levodopa/Carbidopa treatment. 
Interventions Patients were randomly assigned to either treatment group and 
told to take their medication the same time each day. Patients 
were either given Levodopa/Carbidopa/Entacapone in the 
following dose 100/25/200mg or Levodopa/Carbidopa 
100/25mg 
Outcomes Primary: UPDRS III 
Secondary: UPDRS I,II and III 
Notes This study looked at both immediate release and slow release, 
I will only be using the immediate release data. 
 




Support for judgement 
Random sequence 
generation (selection bias) 




Low risk Study medication was over encapsulated 
by Farmasierra (Spain) to prevent 
unblinding of the treatment. 


















Other bias Low risk 
 






Characteristics of excluded studies  
Bet 2008  
Reason for 
exclusion 
This article didn't compare Entacapone to placebo or use any 
control. It also only looked at UPDRS III and didn't include II. 
Durif 2001  
Reason for 
exclusion 
This article didn't compare Entacapone to placebo or a control, 
also it was conducted as an open study therefore if this study 
was included in the meta-analysis there would be bias. 
Gershanik 2003  
Reason for 
exclusion 
This article only had data for Entacapone and no control or 
placebo. 
Kieburtz 1997  
Reason for 
exclusion 
This article only had data for UPDRS II (ADL) and no data for 
UPDRS III. 
Larsen 2003  
Reason for 
exclusion 
This was a follow up to a study that was carried out by Rinne 
1998 which I have already included. 
Mizuno 2007  
Reason for 
exclusion 
The outcomes of this article were not consistent with the other 
papers, it focused on 'on time' rather that UPDRS scores. 
Olanow 2013  
Reason for 
exclusion 
This was a review type article, and although it focused on the 
correct subject, it didn't contain primary data, only a review of 
previous existing studies. 
Piccini 2000  
Reason for 
exclusion 
This article only looked at UPDRS score III and did not include 
UPDRS score II.  
Reichmann 2005  
Reason for 
exclusion 
UPDRS was not the primary outcome of this paper, they 
reported the baseline scores but did not include them as final 
scores in the detail I needed.  
Footnotes 
 




Summary of findings tables  
1 Levodopa+DDCI+Entacapone versus Levodopa+DDCI+Placebo in the 
treatment of Parkinson's disease Table 2.6 
Levodopa+DDCI+Entacapone versus Levodopa+DDCI+Placebo in the treatment of Parkinson's 
disease 
Patient or population: Parkinson's disease 
Settings: 
Intervention: Levodopa+DDCI+Entacapone versus Levodopa+DDCI+Placebo 


































157 per 1000 




258 per 1000 


























-6.1 to 10 
UPDRS 
II+III 
The mean change in updrs 
scores (ii+iii) from baseline to 
finish in the intervention 
groups was 
2.15 lower 





























135 per 1000 




145 per 1000 
(123 to 166) 
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in 
footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in 
the comparison group and the relative effect of the intervention (and its 95% CI). 
CI: Confidence interval; RR: Risk ratio; 
GRADE Working Group grades of evidence 
High quality: Further research is very unlikely to change our confidence in the estimate of effect. 
Moderate quality: Further research is likely to have an important impact on our confidence in the 
estimate of effect and may change the estimate. 
Low quality: Further research is very likely to have an important impact on our confidence in the 




estimate of effect and is likely to change the estimate. 
Very low quality: We are very uncertain about the estimate. 
Footnotes 
1 The range has been used to demonstrate the variety of the scores from both ends 
of the spectrum. 
2 A lower score indicates a positive improvement and favours the treatment group in 
the analysis 1.2 (change in UPDRS scores II+III from baseline to end of study). 
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Data and analyses  
1 Levodopa/DDCI/Entacapone versus Levodopa/DDCI/Placebo Table 2.7 
Outcome or 
Subgroup 
Studies Participants Statistical Method 
Effect 
Estimate 




1.2 Change in UPDRS 
scores (II+III) from 
baseline to finish 
7 2656 Mean Difference (IV, 
Random, 95% CI) 
-2.15 [-4.66, 
0.36] 
1.4 Adverse Effects- 
Dyskinesia 
8 2930 Risk Difference (M-H, 
Fixed, 95% CI) 
0.05 [0.03, 
0.07] 
  
 
 
 
 
 
 
 
